Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Levetiracetam: a long-ter… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Levetiracetam: a long-term follow-up study of efficacy and safety.

Artikel i vetenskaplig tidskrift
Författare J Bauer
Elinor Ben-Menachem
G Krämer
W Fryze
S Da Silva
D G A Kasteleijn-Nolst Trenité
Publicerad i Acta neurologica Scandinavica
Volym 114
Nummer/häfte 3
Sidor 169-76
ISSN 0001-6314
Publiceringsår 2006
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Sidor 169-76
Språk en
Länkar dx.doi.org/10.1111/j.1600-0404.2006...
Ämnesord Adolescent, Adult, Aged, Aged, 80 and over, Anticonvulsants, administration & dosage, adverse effects, Child, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Epilepsy, drug therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Piracetam, administration & dosage, adverse effects, analogs & derivatives, Treatment Outcome
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

OBJECTIVES: To evaluate the efficacy and safety of long-term add-on treatment with levetiracetam 1,000-4,000 mg/day. PATIENTS AND METHODS: In this multicenter, open-label follow-up study, 505 patients, from 10 European countries, who had benefited from previous add-on treatment with levetiracetam in a clinical trial or compassionate-use program were enrolled; 274 (54.3%) stayed to the end. Most then continued levetiracetam by prescription or in a named patient program, where it was not yet commercially available. Mean treatment duration was 1,045 days (range: 24 days to >7 years). Median daily dosage was 3,000 mg/day (range: 250-6,000 mg/day), with 250 (49.5%) patients receiving levetiracetam for >3 years. RESULTS: Median total and partial seizure frequency per week over the evaluation period were 0.8 and 0.7; seizure frequency per week was generally stable over time and remained low. There was a probability of 6.6% of remaining seizure-free for the first 3 years, and of 18.9% of having a seizure-free period of at least 3 years at any time. Most adverse events were mild or moderate and unrelated to study drug. Levetiracetam was well tolerated, and provided stable seizure control during long-term treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?